

T: 0131-244 2528

E: irene.fazakerley@scotland.gsi.gov.uk



**IMMEDIATE MESSAGE TO:**

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

18 June 2013

Dear Healthcare Professional,

**DRUG ALERT CLASS 1 no.17 2013 – IMMEDIATE**

Please see the attached drug alert for onward transmission as below.  
Could all Directors of Pharmacy please forward this alert to:-

- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- Accident & Emergency Departments
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

**IRENE FAZAKERLEY**

Finance,e-Health and Pharmaceuticals Directorate

# DRUG ALERT

## CLASS 1 MEDICINES RECALL

Action Now – including out of hours  
HOSPITAL PHARMACY AND WARD LEVEL RECALL

Date: 18 June 2013

EL (13)A/17

Our Ref: MDR 25-06/13

Dear Healthcare Professional,

### Gilead Sciences International Limited

**AmBisome 50mg Powder for Solution for Infusion** **PL 16807/0001**  
**(Liposomal Amphotericin B)**

Batch Number	Expiry Date	Pack Size	First Distributed
042263AD1	30 Jun 2015	10 x 50mg vials	30 Nov 2012
042264AD	30 Jun 2015	10 x 50mg vials	07 Dec 2012
042285AD	31 Aug 2016	10 x 50mg vials	04 Jan 2013
0422A6AD	31 Oct 2016	10 x 50mg vials	14 Mar 2013
042311AD	31 Jan 2017	10 x 50mg vials	15 May 2013

Gilead Sciences International Limited is recalling the above batches as a precautionary measure due to a potential lack of sterility assurance. No complaints or adverse reaction reports which may be related to this issue have been received by the company to date.

Remaining stocks of affected batches should be quarantined and returned to the original supplier for credit. For stock enquiries, please contact Gilead Customer Services by phone on 01223 897400 or by email at [ukcustomer.services@gilead.com](mailto:ukcustomer.services@gilead.com)

For medical information enquiries please contact Gilead Medical Information by phone on 01223 897312 or by email at [ukmedinfo@gilead.com](mailto:ukmedinfo@gilead.com)

Recipients of this Drug Alert should bring it to the attention of relevant professionals by copy of this letter.

Yours faithfully

**Alison Bunce**  
**Pharmaceutical Assessor**  
**Defective Medicines Report Centre**  
**151 Buckingham Palace Road**  
**London**  
**SW1W 9SZ**  
**Telephone +44 (0)20 3080 6574**